205 results about "Deletion mutant" patented technology

The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.

The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.

The invention relates to a mammal cell high-efficiency expression vector pSNEO. The vector is constructed on the basis of neomycin resistance screening gene NEO by combined strategy of weakening screening gene expression and reinforcing target gene expression. The screening gene weakening comprises the following two sides: introducing deletion mutant into the promoter to implement transcription weakening of the screening gene, and introducing a hairpin structure sequence before the translation initial site of the screening gene to implement the translation weakening of the screening gene. The expression reinforcement of the target gene is implemented by adding a transcription control element WPRE sequence between polyclone site and polyA tail of the target gene expression frame. The pSNEO vector can conveniently and quickly complete the construction of the stable high-expression cell strain of the target gene, and provides a new tool for preparing the high-polymer recombinant protein.

An E. coli host strain was engineered wherein genes adhE, IdhA, frdB, and pfIB were disrupted and novel butanol dehydrogenase gene, sadB, from Achromobacter xylosoxidans, was added to produce the isobutanol production host.

The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease.

The invention relates to a rice salt-tolerant gene OsRR22 mutant, an encoded amino acid sequence thereof, a plant and a making method of the mutant, and belongs to the technical field of plant biology. A CRISPR/Cas9 technology is sued to edit self-selected rice variety WDR58 with rice salt-tolerant gene OsRR22 to obtain a rice salt-tolerant gene OsRR22 function deleted mutant new germplasm WDR58-cas-1 with important application values. The mutant can significantly increase the salt tolerance of rice, and can be applied to high-yielding salt-tolerant rice breeding.

Factor XDELTA analogues are provided, as well as pharmaceutical preparations containing such analogues and methods of preparing such analogues. The factor XDELTA analogues have a deletion of the amino acids Arg180 to Arg234 and a modification in the region of the amino acid sequence between Gly173 and Arg179 of the factor X amino acid sequence. Such analogues can include a processing site not normally present in factor X, thus allowing for selective conversion of the analogue to an active form. The analogues and preparations have utility in the treatment of a number of blood coagulation disorders.

The invention discloses a pullulanase mutant with improved secretion efficiency and heat stability and a preparation method of the pullulanase mutant, and belongs to the field of gene engineering and enzyme engineering. The secretion efficiency and the heat stability of pullulanase are improved through structural domain deletion mutation; deleted structural domains are CBM41, X45 and X25 structural domains or combinations thereof; and the mutation technical scheme capable of improving the secretion efficiency and the heat stability of pullulanase is provided. The obtained pullulanase structural domain deletion mutant has at least one of changed properties as follows: 1), the extracellular secretion efficiency is improved after recombinant bacteria are fermented; and 2), and the heat stability is improved under the conditions of pH 4.0-5.0 and 60 DEG C. Compared with natural pullulanase, structural domain deletion mutants are more suitable for production, preparation and applications of the pullulanase.

The invention relates to a method for using the genetic engineering method to prepare insect Thanatin and fifteenth amino acid (T) deletion mutant thereof. The invention is characterized in that the method has low cost and simple post processing, thereby being commercially produced in the large scale.

The invention discloses a method for improving erythrocin yield through a negative control gene SACE_3446 on an inactivation saccharopolyspora erythraea chromosome. Saccharopolyspora erythraea is used for producing erythrocin. The erythrocin and derived drugs of the erythrocin such as clarithromycin, azithromycin and telithromycin are used widely in clinic. Erythrocin high-producing strain screening is very important in industrial production. The erythromycin biosynthesis negative control gene SACE_3446 is screened from a saccharopolyspora erythraea TetR family. Compared with erythrocin yield of an original strain, deletion mutants of the saccharopolyspora erythraea SACE_3446 is improved remarkably, the erythrocin is returned to low yield after gene complementation of the SACE_3446, and therefore the SACE_3446 gene is a erythromycin biosynthesis negative control gene. The inactivation saccharopolyspora erythraea SACE_3446 gene can improve the erythrocin yield through a genetic engineering way. Due to the fact that erythromycin biosynthesis gene control is a network system, upstream and downstream control factors acted by SACE_3446 control factors can be found by using the SACE_3446 as an object. The erythrocin yield can also be improved by changing upstream or downstream control factor genes of the saccharopolyspora erythraea SACE_3446 control factors.

The invention constructs an expression vector suitable for expressing an exogenous gene in a chlorella nitrate reductase deletion mutant by using a Ubiquitin promoter and an omega enhancer as starting elements and the nitrate reductase gene NR. An objective gene is converted to the mutant by using an economic and simple chlorella PEG conversion method and employing the Chlorella ellipsoidea nitrate reductase deletion mutant as a receptor. The transgene chlorella wall breaking technology is optimized, the expressed exogenous gene has normal biological activity and is stably inherited in a culture medium without antibiotics. The results of the invention can high efficiently and safely be used to express the exogenous gene which does not suit to be expressed by the normal genetic engineering expression system (such as the escherichia coli and yeast) by using the genetic engineering technology and the Chlorella ellipsoidea nitrate reductase deletion mutant as a vector.

The invention relates to a recombinant heat-resistant DNA polymerase. The recombinant heat-resistant DNA polymerase comprises a DNA binding structural domain, a protein structural domain connector and a heat-resistant DNA polymerase without 3'-5' nucleic acid exonuclease activity, wherein the DNA binding structural domain is a Sso7d structural domain, HMf protein, or an HhH structural domain of DNA topoisomerase V from methanothermus fervidus; the heat-resistant DNA polymerase without the 3'-5' nucleic acid exonuclease activity is a deletion mutant of Taq, Tth, Tma, Pfu, Deep, Vent or Tgo DNA polymerase. The invention also provides the application of the recombinant heat-resistant DNA polymerase in DNA sequencing. The continuity and the extending speed of the recombinant heat-resistant DNA polymerase disclosed by the invention are obviously enhanced; the time is shortened during a PCArg reaction sequencing process; by using the sequenase provided by the invention, longer reading length and higher sequencing success rate can be achieved.

The invention relates to an application of Arabidopsis gene AtSDH, in particular to an application of the gene in regulating plant stress resistance and application of the gene in culturing anti-stress transgenic plant variety. In the invention, analysis of over-expression transgenic plants and deletion mutants to sensitivity and growth of ABA under stress condition is used to determine that the role of AtSDH in Arabidopsis stress is related to the plant hormone ABA, thereby providing important basis for understanding the role of plant sorbitol metabolism in plant stress resistance. When used in agricultural production, the gene can enable the seedlings and plants to more tolerate stress and lays theoretical foundation for culturing new variety of transgenic crops. Compared with wild Arabidopsis, the sensitivity of the transgenic Arabidopsis with over-expression of AtSDH gene to ABA is reduced and the capacity of the seedlings and plants to draught tolerance, high salt tolerance and the like is improved.

The invention discloses a watermelon oxysporum pathogenic FonAGL3 gene as well as a deleted DNA fragment, a deletion mutant and application thereof, and aims to solve the technical problem of biological prevention and treatment on watermelon oxysporum. A pathogenic gene FonAGL3 derived from watermelon fusarium oxysporum is analyzed and screened by inserting watermelon oxysporum T-DNA into a mutant library, by utilizing the homologous gene replacement principle, DNA fragments of the target gene FonAGL3 are replaced by gene DNA fragments of a resistance gene hygromycin B (HPH), a FonAGL3 gene deletion mutant is obtained by establishing a gene deletion carrier and implementing genetic transformation of a wild strain FON-11-06, and the FonAGL3 mutant bacterium has a good wilt prevention and treatment effect and is environmental-friendly and low in prevention and treatment cost.

The invention provides for SPARC polypeptides with a mutation corresponding to a deletion of the third glutamine in the mature form of the human SPARC protein, nucleic acids encoding such polypeptides, antibodies against such polypeptides, and methods of the use of such polypeptides, nucleic acids, and antibodies.

The invention discloses a thellungiella V-pyrophosphatase gene (TsVPI) promoter sequence and the application of a deletion mutant thereof. A clone carrying a TsVPI promoter is screened from a genomiclibrary of halophyte thellungiella, a 2200 nucleotide sequence positioned on the upstream of a TsVPI coding frame 5' is truncated as an overall-length promoter, promoter snippets with different lengths are obtained through PCR amplification, and then the promoter snippets are respectively blended with gus genes to be recombined into a plant expression vector to be converted into Arabidopsis; the TsVPI promoter and a part of the deletion mutant thereof are determined as salt-stress inducible type promoters by detecting the GUS enzymatic activity of transgenic plants, wherein a T5 promoter not only has a short sequence (667bp) but also has root specificity, and the TsVPI promoter and the T5 promoter are respectively connected with betA genes from colibacillus to be transmitted into tobaccosand corns so as to determine that the TsVPI promoter and the T5 promoter can normally exert functions in the transgenic tobaccos and the transgenic corns, are salt-stress inducible type strong promoters and have important application value in the industrialization development of plant gene engineering.

Live attenuated Eastern Equine Encephalitis (EEE) vaccines that outperform the PE-6 vaccine in mice aerosol challenged with >1,000×LD50. Candidates include four furin-cleavage deletion mutants and one E3 deletion mutant. Each vaccine provided protection in birds against antigenically distinct North and South American strains of EEE. The PE-6 vaccine does not provide protection against South American EEEs. Animals inoculated with each of the vaccines of the invention developed neutralizing antibodies to EEE.

The invention relates to a genetic engineering technology, in particular to a superantigen mutant protein gene of enterotoxin C2 and a method for cloning, expressing and preparing the same. The superantigen mutant protein gene of the enterotoxin C2 comprises base sequences in tables of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4. Allogenetic expression of the superantigen mutant protein gene provides development potential of the enterotoxin C2 in the anti-tumor aspect; and the superantigen mutant protein gene performs deletion mutant on an amino terminal thereof on the basis of SEC2, the amino terminal affects the biological activity, and mutant protein kept with the superantigen activity is expected to be obtained on the basis simultaneously. The superantigen mutant protein gene of the enterotoxin C2 applied to preparing a superantigen anti-tumor biological agent has the characteristics of high yield, stable production, convenient purification and the like.

The present invention relates to novel antibodies, in particular to antibodies against deletion mutants of the epidermal growth factor receptor, and in particular to the type III deletion mutant EGFRvIII. The present invention also relates to human monoclonal antibodies directed against deletion mutants of the epidermal growth factor receptor, and in particular EGFRvIII. The invention also provides diagnostic and therapeutic formulations of these antibodies, and immunoconjugates thereof.

The invention belongs to animal bacterium gene engineering field, relates to form stem of Actinobacillus pleuropneumoniae APP-1-mut01 digene deletion mutants without fastness label, preparing vaccine and application thereof. The invention gets a stem of Actinobacillus pleuropneumoniae APP-1-mut01 (storing number is CCTCC NO; M207005). The stem absents two main toxin gene activity factors apxIC and apxIIC of Actinobacillus pleuropneumoniae APP-1-mut01, produces toxin albumen ApxIA and ApxIIA without toxin, but these two toxin albumen also have immunity originality. The invention also discloses producing vaccine of Actinobacillus pleuropneumoniae APP-1-mut01 using the digene deletion mutants stem and application thereof. The digene deletion vaccine can irritate pig generate protective immunity reaction to resist isogeny and nonhomology serum wild strain of actinobacillus pleuropneumoniae to prevent infection thereof.

A method is described for the detection of a rare deletion mutant allele in a population of wild-type individuals. DNA samples from the individuals are subjected to a modified form of polymerase chain reaction (PCR) which favors the replication of truncated DNA strands over the synthesis of wild-type full length strands. The preferred way to bias the process toward the synthesis of truncated DNA strands is by limiting the extension step in the PCR reaction protocol. This process permits the convenient detection of a deletion mutant allele from a population of 1000 wild type individuals with the full length allele.